Identification of an m6A-Related Signature as Biomarker for Hepatocellular Carcinoma Prognosis and Correlates with Sorafenib and Anti-PD-1 Immunotherapy Treatment Response

<div>Association of risk signature with sorafinib treatment response of GSE109211 cohort. (a) Difference of risk score between sorafinib treatment responders and nonresponders. (b) AUC of risk signature in predicting in sorafinib treatment response.</div>

Disease Markers

fig8

Figure 8

Figure 8: Identification of an m6A-Related Signature as Biomarker for Hepatocellular Carcinoma Prognosis and Correlates with Sorafenib and Anti-PD-1 Immunotherapy Treatment Response 

Figure 8 | Identification of an m6A-Related Signature as Biomarker for Hepatocellular Carcinoma Prognosis and Correlates with Sorafenib and Anti-PD-1 Immunotherapy Treatment Response 